公开(公告)号：US08962891B2

公开(公告)日：2015-02-24

申请号：US12742045

申请日：2008-11-09

Applicant: Arie Dagan ,  Shimon Slavin ,  Shimon Gatt ,  Jeremy Zahavi

Inventor： Arie Dagan ,  Shimon Slavin ,  Shimon Gatt ,  Jeremy Zahavi

IPC: C07C215/10 ,  A61K31/13

CPC classification number: C07C215/12 ,  A61K31/133 ,  A61K31/4745 ,  A61K31/513 ,  C07C215/10 ,  Y02A50/409 ,  Y02A50/411

Abstract: The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.

Abstract translation: 本发明提供了新的表示为式（II）化合物的神经酰胺类似物。 这些新型类似物表现出显着的抗癌作用，因此作为治疗细胞增殖性疾病，神经变性疾病，代谢相关病症，感染性疾病和免疫相关疾病的药物组合物提供。 本发明还提供组合的组合物和试剂盒，其将式（II）的新型神经酰胺类似物与另外的治疗剂组合。

公开(公告)号：US20120148550A1

公开(公告)日：2012-06-14

申请号：US13377558

申请日：2010-06-10

Applicant: Chaya Brodie ,  Shimon Slavin

Inventor： Chaya Brodie ,  Shimon Slavin

IPC: A61K35/30 ,  A61P25/00 ,  A61P25/28 ,  C12N5/02

Abstract: Some embodiments of the invention comprise methods, systems, and compositions to selectively induce, whether in vitro or in vivo, the neuronal differentiation of multipotent stromal cells through the application of microRNAs, including but not limited to miRNA-124, miRNA-137 and/or miRNA-9* expression products of those miRNAs, and molecules and compositions containing functional elements of those miRNAs. Some embodiments of the invention also comprise the therapeutic administration and use of such induced cells to treat mammalian injuries and diseases, including but not limited to, nervous system injuries or diseases that may otherwise result in decreased cell or system function.

Abstract translation: 本发明的一些实施方案包括方法，系统和组合物，其通过应用微小RNA（包括但不限于miRNA-124，miRNA-137和/或核糖体）选择性地诱导多潜能基质细胞的体外或体内神经元分化， 或miRNA-9 *表达产物，以及含有这些miRNA功能元件的分子和组合物。 本发明的一些实施方案还包括治疗性施用和使用这种诱导的细胞来治疗哺乳动物的损伤和疾病，包括但不限于神经系统损伤或可能导致细胞或系统功能降低的疾病。

公开(公告)号：US08071641B2

公开(公告)日：2011-12-06

申请号：US10589623

申请日：2005-02-16

Applicant: Lola Weiss ,  Michael Zeira ,  Raphael Mechoulam ,  Shimon Slavin ,  Ruth Gallily

Inventor： Lola Weiss ,  Michael Zeira ,  Raphael Mechoulam ,  Shimon Slavin ,  Ruth Gallily

IPC: A61K31/05 ,  A61K31/192 ,  A61K31/353

CPC classification number: A61K31/05 ,  A61K36/185

Abstract: Use of a cannabidiol for the manufacture of a medicament identified for the treatment or prevention of diabetes and/or insulitis.

Abstract translation: 使用大麻二醇来制造用于治疗或预防糖尿病和/或胰岛炎的药物。

公开(公告)号：US20080213332A1

公开(公告)日：2008-09-04

申请号：US11667492

申请日：2005-11-10

Applicant: Shimon Slavin ,  Ido J. Kilemnik

Inventor： Shimon Slavin ,  Ido J. Kilemnik

IPC: A61F2/00 ,  C12N5/06 ,  C12M1/00 ,  A61K35/32 ,  A61P1/00 ,  A61K35/36 ,  A61K35/34 ,  A61K35/12

CPC classification number: C12N5/0605 ,  A61K35/48 ,  A61K35/50 ,  A61L27/3604 ,  A61L27/3804 ,  A61L27/3839 ,  C12N5/0647 ,  C12N2506/02

Abstract: A method of processing an organ is disclosed. The method comprises: (a) placing an organ in a sealable container; (b) disrupting the structure of said organ to yield a cell suspension; and (c) transferring said cell suspension to a sealable cell-suspension storage container, thereby isolating cells of said organ, wherein said sealable container, wherein said disrupting and said transferring are all performed substantially in a continuous vessel.

Abstract translation: 公开了一种处理器官的方法。 该方法包括：（a）将器官置于可密封的容器中; （b）破坏所述器官的结构以产生细胞悬浮液; 和（c）将所述细胞悬浮液转移到可密封的细胞 - 悬浮液储存容器中，从而分离所述器官的细胞，其中所述可密封容器，其中所述破坏和所述转移都基本上在连续容器中进行。

公开(公告)号：US06447767B1

公开(公告)日：2002-09-10

申请号：US09506082

申请日：2000-02-16

Applicant: Shimon Slavin ,  Tatyana Prigozhina

Inventor： Shimon Slavin ,  Tatyana Prigozhina

IPC: A61K3800

CPC classification number: A61K39/001 ,  A01K67/0271 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/14 ,  A61K35/28 ,  A61K2035/122 ,  A61K2039/5158

Abstract: The present invention features a method of inducing donor-specific tolerance in a host. Tolerogenic treatments of the present invention may be administered to a host prior to transplantation of donor-derived materials. The tolerogenic treatment involves (1) administering an immunosuppressive agent to a host mammal in a non-myeloablative regimen sufficient to decrease, but not necessarily to eliminate, the host mammal's functional T lymphocyte population; (2) infusing donor antigens from a non-syngeneic donor into the host mammal; (3) eliminating those host T lymphocytes responding to the infused donor antigens using a non-myeloablative dose of lymphocytotoxic or tolerizing agent; and (4) administering donor hematopoietic cells to the host mammal. Donor lymphoid cells used for cell therapy of a host mammal can be depleted of host specific immunological reactivity by methods essentially similar to those use for tolerizing a host mammal prior to transplantation.

公开(公告)号：US5928639A

公开(公告)日：1999-07-27

申请号：US735496

申请日：1996-10-23

Applicant: Shimon Slavin

Inventor： Shimon Slavin

IPC: A61K38/00 ,  A61K31/215 ,  A61K35/12 ,  A61K35/14 ,  A61K35/17 ,  A61K35/26 ,  A61K38/20 ,  A61K38/21 ,  A61K39/395 ,  A61K45/00 ,  A61P35/00 ,  C12N5/0783 ,  A61K35/28 ,  A61K38/19 ,  C12N5/08

CPC classification number: C12N5/0636 ,  A61K35/17 ,  A61K38/2013 ,  A61K38/204 ,  A61K38/2046 ,  A61K38/217 ,  A61K2035/124 ,  C12N2501/23

Abstract: Methods have been discovered for treating minimal residual disease following removal of most or a substantial fraction of malignant cells from a cancer patient. An autologous stem cell transplant is performed on the patient. Following partial hematopoiesis recovery, the patient is infused with allogeneic peripheral blood lymphocytes, either alone or in combination with in vivo or in vitro cytokine. The infused allogeneic lymphocytes engender an anti-malignant cell response and can be instrumental in prevention of disease relapse.

公开(公告)号：US5866546A

公开(公告)日：1999-02-02

申请号：US844518

申请日：1997-04-18

Applicant: David Gross ,  Lola Weiss ,  Shimon Slavin ,  Hiroshi Okamoto

Inventor： David Gross ,  Lola Weiss ,  Shimon Slavin ,  Hiroshi Okamoto

IPC: A61K38/17 ,  A61K38/28 ,  A61K45/06 ,  A61K48/00 ,  C07K14/47 ,  A61K31/47 ,  A61K38/00

CPC classification number: C07K14/474 ,  A61K38/1709 ,  A61K38/28 ,  A61K45/06 ,  A61K48/00 ,  C12N2799/022 ,  Y10S514/866

Abstract: A composition for the treatment of diabetes and a method of use thereof. composition includes an immunoregulator, preferably Linomide, and a .beta. cell proliferative agent, preferably reg protein. The composition has been shown to be effective in both inhibiting the progression of diabetes, and reversing the course of the disease, in the NOD mouse model.

Abstract translation: 用于治疗糖尿病的组合物及其使用方法。 组合物包括免疫调节剂，优选Linomide和β细胞增殖剂，优选reg蛋白。 在NOD小鼠模型中，该组合物已被证明在抑制糖尿病进展和逆转疾病过程中都是有效的。

公开(公告)号：US5461034A

公开(公告)日：1995-10-24

申请号：US79637

申请日：1993-06-18

Applicant: Gideon A. Rodan ,  John W. Jacobs ,  Mohinder K. Sardana ,  Dan Gazit ,  Michael Chorev ,  Andras Muhlrad ,  Arye Shteyer ,  Nura Mansur ,  Zvi Greenberg ,  Shimon Slavin ,  Olga Gurevitch ,  Itai A. Bab

Inventor： Gideon A. Rodan ,  John W. Jacobs ,  Mohinder K. Sardana ,  Dan Gazit ,  Michael Chorev ,  Andras Muhlrad ,  Arye Shteyer ,  Nura Mansur ,  Zvi Greenberg ,  Shimon Slavin ,  Olga Gurevitch ,  Itai A. Bab

IPC: A61K38/00 ,  C07K14/51 ,  A61K38/08 ,  A61F2/02 ,  A61K35/32 ,  A61K38/39

CPC classification number: C07K14/51 ,  A61K38/00 ,  Y10S530/84 ,  Y10S530/841

Abstract: A biochemically pure polypeptide(s), termed osteogenic growth polypeptide (OGP), which exhibits stimulatory effects on osteoblastic cells, in vivo bone formation and hemopoietic reconstruction. OGP, identified from regenerating bone marrow, has an amino acid sequence ofAla-Leu-Lys-Arg-Gln-Gly-Arg-Thr-Leu-Tyr-Gly-Phe-Gly-Gly.

Abstract translation: 称为成骨生长多肽（OGP）的生物化学纯多肽，其对成骨细胞表现出刺激作用，体内骨形成和造血重建。 由再生骨髓鉴定的OGP具有Ala-Leu-Lys-Arg-Gln-Gly-Arg-Thr-Leu-Tyr-Gly-Phe-Gly-Gly的氨基酸序列。

公开(公告)号：US09283199B2

公开(公告)日：2016-03-15

申请号：US12796804

申请日：2010-06-09

Applicant: Shalva Mardi ,  Rosa Mardi ,  Gymsher Mardi ,  Laura Mardi ,  Shimon Slavin

Inventor： Shalva Mardi ,  Rosa Mardi ,  Gymsher Mardi ,  Laura Mardi ,  Shimon Slavin

IPC: A61K31/19 ,  A61K31/194 ,  A61K31/22 ,  C07C59/315 ,  C07C69/63 ,  C07C69/708

CPC classification number: A61K31/19 ,  A61K31/194 ,  A61K31/22 ,  C07C59/315 ,  C07C69/63 ,  C07C69/708

Abstract: Halogenated aliphatic carboxylic acids, salts and/or oligomers or polymers thereof, which exhibit a devitalizing effect of neoplastic tissues, are disclosed. Methods and uses that utilize these compounds for the treatment of medical conditions associated with a neoplastic tissue are also disclosed. Further disclosed are methods and uses that utilize these compounds for reducing or abolishing blood and lymph as well local dissemination of malignant neoplastic cells during a surgical removal thereof, thereby preventing recurrences and distance metastases, and/or inducing immune response to potentially malignant, pre-malignant and/or malignant cells. Further disclosed are novel oligomeric forms of halogenated aliphatic carboxylic acids, pharmaceutical compositions containing same and uses thereof.

Abstract translation: 公开了表现出肿瘤组织失活作用的卤代脂族羧酸，其盐和/或低聚物或聚合物。 还公开了利用这些化合物治疗与肿瘤组织相关的医学病症的方法和用途。 进一步公开的是使用这些化合物来减少或消除血液和淋巴的方法和用途，以及恶性肿瘤细胞在手术切除期间的局部扩散，从而防止复发和距离转移，和/或诱导对潜在的恶性， 恶性和/或恶性细胞。 还公开了卤代脂族羧酸的新型低聚形式，含有它们的药物组合物及其应用。

公开(公告)号：US08741315B2

公开(公告)日：2014-06-03

申请号：US12677543

申请日：2008-09-11

Applicant: Ilan Volovitz ,  Lea Eisenbach ,  Irun R. Cohen ,  Zvi Ram ,  Shimon Slavin

Inventor： Ilan Volovitz ,  Lea Eisenbach ,  Irun R. Cohen ,  Zvi Ram ,  Shimon Slavin

IPC: A61K39/00 ,  A61K35/30

CPC classification number: A61K39/0011 ,  A61K2039/5152

Abstract: A method of treating cancer in an immune-privileged site of a subject in need thereof is provided. The method comprises systemically administering to an area outside the immune-privileged site of the subject, a therapeutically effective amount of naive, viable cells of a tumor of the subject, the tumor being in the immune-privileged site so as to generate an immune response in the subject, thereby treating the cancer in the immune-privileged site of the subject.

Abstract translation: 提供了在有需要的受试者的免疫特异部位中治疗癌症的方法。 该方法包括系统地施用受试者的免疫特权部位之外的区域，治疗有效量的受试者肿瘤的天真，活的细胞，肿瘤位于免疫特异位点以产生免疫应答 从而治疗受试者的免疫特异部位的癌症。